Pacific Biosciences Continues to Navigate Rough Waters

Photo of author
Written By Saad Sarfaraz

Pacific Biosciences specializes in genetic sequencing technology with its Single-molecule, Real-Time (SMRT) sequencing technology. Despite its innovative approach, Pacific Biosciences faces significant challenges, including higher perceived error rates compared to competitors like Illumina (ILMN), impacting its cost and time efficiency.

Financial strains and high operational risks raise concerns over Pacific Biosciences as Potential Investment.

Challenges and Competition in Sequencing Technology

Credits: DepositPhotos

Pacific Biosciences is known for its SMRT sequencing technology, which offers long-read sequencing capabilities. However, SMRT is perceived to have higher error rates compared to Illumina’s platforms, necessitating multiple reads to achieve high accuracy.

This increases the cost and time involved, making it less attractive to budget-conscious and time-sensitive researchers and clinical labs.

Market Competition

In addition to Illumina, Pacific faces competition from Oxford Nanopore, which provides long-read sequencing with portable and flexible devices. Although Pacific has launched HiFi sequencing to improve accuracy, customer skepticism persists.

The company’s ongoing efforts to debunk error rate myths suggest lingering hesitancy among its customer base.

Q1 Earnings and Financial Strains

Pacific Biosciences’ Q1 earnings highlight its financial challenges. The company reported total revenue of $38.8 million, slightly down from $38.9 million in Q1 2023, missing expectations by $3.23 million.

Product revenue constituted $35 million, with a gross margin of 36%, significantly lower than Illumina’s 71% gross margin in the same quarter. Despite an improvement from last year’s 27%, the gross margin remains low.

High SG&A and R&D Expenses

Pacific’s SG&A expenses were $43.753 million, surpassing total revenues. R&D spending was also high at $43.455 million, contributing to a net loss of $78.178 million for Q1. The company’s share count increased from 242,032 at the end of last year to 269,578.

Financial Health

As of Q1, Pacific reported $76.646 million in cash and cash equivalents and $485.268 million in investments, with total current assets of $677 million against $72.95 million in current liabilities, indicating a healthy current ratio.

However, the company has $892.545 million in long-term convertible senior notes and a quarterly cash burn of $75.682 million. Based on historical data, Pacific has nearly two years of cash runway, but future capital raising may be necessary.

Risk/Reward Analysis and Investment Recommendation

Pacific Biosciences faces significant operational and financial risks. The genomic market is highly competitive, with established players like Illumina dominating. PACB’s niche SMRT sequencing technology commands a small market share amid high SG&A costs, declining product revenues, and low gross margins.

The need for substantial R&D investment exacerbates the company’s financial woes, leading to considerable net losses and debt obligations.

Investment Outlook

Credits: DepositPhotos

Given the high risk and low return potential, PACB presents a precarious investment. The company’s enterprise value of nearly $900 million does not justify its current performance and future prospects.

In conclusion, Pacific Biosciences is navigating a challenging landscape in the gene sequencing market. While the company has potential, especially if perceptions of its technology improve or demand for long-read sequencing increases, the current financial and operational risks overshadow these possibilities.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.